Tier 2 — strong

Benefits of Quercetin on Glycated Hemoglobin, Blood Pressure, PiKo-6 Readings, Night-Time Sleep, Anxiety, and Quality of Life in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Aikaterini E Mantadaki, Manolis Linardakis, Maria Tsakiri, Stella Baliou, Persefoni Fragkiadaki, Elena Vakonaki, Manolis N Tzatzarakis, Aristidis Tsatsakis, Emmanouil K Symvoulakis
Journal of clinical medicine 2024 13(12):3504

Bibliography

PubMed
PMID 38930033
PubMed Central
PMC11205103
DOI
10.3390/jcm13123504
Funding
Reported funding/support: This research received no external funding.
Competing interests
Reported disclosure: The authors declare no conflicts of interest.

Study snapshot

DesignRandomized open-label usual-care controlled trial
ModelHuman intervention research
Sample100 randomized adults with type 2 diabetes; 88 completed
InterventionQuercetin 500 mg/day added to usual care
Duration12 weeks supplementation, 8-week washout, then 12 further weeks
EndpointsBlood pressure; Glucose and insulin measures; Cognitive, mood, or sleep measures

What the study showed, in plain terms

Published in 2024, this source examined cardiovascular and metabolic health. Design: Randomized open-label usual-care controlled trial. Sample/model: 100 randomized adults with type 2 diabetes; 88 completed. The exposure or intervention was Quercetin 500 mg/day added to usual care. Follow-up or treatment period: 12 weeks supplementation, 8-week washout, then 12 further weeks.

The intervention group showed better HbA1c, systolic pressure, respiratory readings and reported sleep, anxiety and quality-of-life measures.

Open-label design and multiple endpoints limit certainty, especially for self-reported outcomes. Related early and telomere reports may share participants.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The intervention group showed better HbA1c, systolic pressure, respiratory readings and reported sleep, anxiety and quality-of-life measures.
  • The recorded outcome domains were Blood pressure; Glucose and insulin measures; Cognitive, mood, or sleep measures.
  • The result applies to the tested exposure: Quercetin 500 mg/day added to usual care; 12 weeks supplementation, 8-week washout, then 12 further weeks.

What this study can and cannot tell us

  • Open-label design and multiple endpoints limit certainty, especially for self-reported outcomes. Related early and telomere reports may share participants.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin Intake and Absolute Telomere Length in Patients with Type 2 Diabetes Mellitus: Novel Findings from a Randomized Controlled Before-and-After Study
Aikaterini E Mantadaki et al. · Pharmaceuticals (Basel, Switzerland) · 2024
Tier 2
The Impact of Three-Month Quercetin Intake on Quality of Life and Anxiety in Patients With Type II Diabetes Mellitus: An Early Data Analysis From a Randomized Controlled Trial
Aikaterini E Mantadaki et al. · Cureus · 2024
Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology